Skip to content
OpenCapital
Get started

Keros Therapeutics KROS Q1 2026 earnings

Reported May 14, 2026 · Before market open

Revenue$367.0KMiss by $1.6M
EPS-$1.21Miss by $0.19
Revenue estimate$1.9M
EPS estimate-$1.02

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$807.1K
EPS estimate-$1.25

Versus estimates

Revenue

Q1 2026$367.0KMiss by $1.6M
Q4 2025$385.0KMiss by $3.3MQ3 2025$14.3MBeat by $10.6MQ2 2025$18.2MBeat by $15.0MQ1 2025$211.2MBeat by $154.6MQ4 2024$3.0MMiss by $19.2M

Diluted EPS

Q1 2026-$1.21Miss by $0.19
Q4 2025-$0.86Miss by $0.37Q3 2025-$0.18Beat by $0.93Q2 2025-$0.76Beat by $0.38Q1 2025$3.62Beat by $3.63Q4 2024-$1.14Beat by $0.22

Ask the moment Keros Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Keros Therapeutics report Q1 2026 earnings?
Keros Therapeutics (KROS) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Keros Therapeutics's Q1 2026 revenue and EPS?
Keros Therapeutics reported revenue of $367.0K and eps of $-1.21 for Q1 2026.
Did Keros Therapeutics beat estimates in Q1 2026?
Revenue missed the consensus estimate of $1.9M by $1.6M. EPS missed the consensus estimate of $-1.02 by $0.19.
How did Keros Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 99.8% from $211.2M a year earlier.
Where can I find Keros Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001664710-26-000029) and the 10-Q periodic report (0001664710-26-000030) directly on SEC EDGAR. The filing index links above go to sec.gov.